SynthesisBiomolecules & biomedicine2025
Prognostic impact of sleep-disordered breathing on mortality and cardiovascular events in renal dialysis: A meta-analysis.
Synthesis in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep-disordered breathing (SDB) is prevalent among patients undergoing renal dialysis, yet its prognostic implications for mortality and cardiovascular outcomes remain unclear. This meta-analysis investigates the relationship between SDB and all-cause mortality as well as major adverse cardiovascular events (MACEs) within this demographic. A systematic search of PubMed, Embase, and Web of Science was conducted from inception to May 29, 2025, focusing on longitudinal observational studies that assessed SDB in adult dialysis patients. The primary outcome analyzed was all-cause mortality, while the secondary outcome was MACEs. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were computed using random-effects models to account for heterogeneity. A total of eleven cohort studies encompassing 656,328 dialysis patients, of which 23,725 had SDB, were included. The results indicated that SDB was significantly associated with an increased risk of all-cause mortality (HR: 1.79, 95% CI: 1.42-2.25; I² = 32%; p < 0.001). Notably, the association was more pronounced in Asian studies (HR: 2.07) compared to non-Asian studies (HR: 1.35; p for subgroup difference = 0.008) and in studies employing polysomnography or pulse oximetry versus those using ICD codes (HR: 2.57 and 2.00 vs. 1.35; p = 0.002). Furthermore, five studies indicated that SDB was linked to an elevated risk of MACEs (HR: 2.68, 95% CI: 1.86-3.85; I² = 0%; p < 0.001). In conclusion, SDB is associated with heightened mortality and cardiovascular risk in patients on renal dialysis. These findings underscore the necessity for increased awareness and management of SDB in this population. However, further interventional studies are required to ascertain whether systematic screening and treatment can enhance clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.